Allarity Therapeutics (NASDAQ:ALLR) & ADMA Biologics (NASDAQ:ADMA) Critical Contrast

ADMA Biologics (NASDAQ:ADMA) and Allarity Therapeutics (NASDAQ:ALLR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Volatility & Risk

ADMA Biologics has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Institutional and Insider Ownership

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for ADMA Biologics and Allarity Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0	3	3	0	2.50
Allarity Therapeutics	1	0	1	0	2.00

ADMA Biologics currently has a consensus price target of $17.50, indicating a potential upside of 27.92%. Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 974.65%. Given Allarity Therapeutics’ higher probable upside, analysts clearly believe Allarity Therapeutics is more favorable than ADMA Biologics.

Profitability

This table compares ADMA Biologics and Allarity Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	35.14%	42.56%	26.96%
Allarity Therapeutics	N/A	-152.77%	-46.50%

Earnings & Valuation

This table compares ADMA Biologics and Allarity Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$519.15 million	5.90	$146.93 million	$0.77	17.77
Allarity Therapeutics	$320,000.00	47.42	-$11.23 million	($0.78)	-1.22

ADMA Biologics has higher revenue and earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Summary

ADMA Biologics beats Allarity Therapeutics on 12 of the 14 factors compared between the two stocks.

About ADMA Biologics

ADMA Biologics is a biopharmaceutical company that develops, manufactures and markets plasma-derived therapies for people with immune deficiencies and certain infectious diseases. Its products include BIVIGAM and ASCENIV, intravenous immune globulin therapies used to treat primary humoral immunodeficiency, and Nabi-HB, an immune globulin used for hepatitis B prevention in specific clinical settings. The company collects human plasma through its U.S. donor centers and processes it into therapies at its manufacturing facility in Boca Raton, Florida.

About Allarity Therapeutics

Allarity Therapeutics is a biotechnology company focused on developing precision-medicine treatments for cancer. Its approach combines oncology drug development with tools intended to help identify patients who may be more likely to respond to a particular therapy. The company’s Drug Response Predictor (DRP) technology analyzes gene-expression data to estimate how a patient’s tumor may respond to a drug. Allarity has developed the platform for use in selecting patients for clinical studies and as a potential companion diagnostic.